Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PMV Pharmaceuticals, Inc. Director's Dealing 2025

Jul 3, 2025

34350_dirs_2025-07-03_8a8cf70e-9c0a-4f60-8525-3d4c7800ba02.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2025-07-01

Reporting Person: Mack David Henry (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-07-01 Common Stock S 58411 $1.0645 Disposed 536133 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 165307 Indirect
Common Stock 147915 Indirect
Common Stock 56978 Indirect

Footnotes

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

F2: Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.

F3: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F4: The shares are held of record by the Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F5: The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.